NCT01161316已完成2 期
Phase-II, Randomized, Multicentre Pilot Study to Evaluate the Safety and Efficacy of the Treatment With mFOLFOX-6 Plus Cetuximab Versus Initial Treatment With mFOLFOX-6 Plus Cetuximab (for 8 Cycles), Followed by Maintenance With Cetuximab Alone as First-line Treatment in Patients With Metastatic Colorectal Cancer (mCRC) and Wild-type KRAS Tumours
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)1 个研究点 分布在 1 个国家目标入组 194 人开始时间: 2010年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 194
- 试验地点
- 1
- 主要终点
- progression-free survival
研究概览
简要总结
The purpose of the study is to evaluate the efficacy and safety of the combination of mFOLFOX-6 plus cetuximab for 8 cycles followed by mFOLFOX-6 plus cetuximab or single agent (s/a) cetuximab as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent.
- •Patients of an age ≥ 18 years and < 71
- •Patients with an ECOG performance status ≤ 2
- •Confirmed histological diagnosis of colorectal carcinoma with metastatic disease and wild-type KRAS.
- •Presence of at least one target lesion that is measurable one-dimensionally (not located in an irradiated region).
- •Life expectancy greater than 12 weeks.
- •First evidence of chemotherapy-naïve metastatic disease. Adjuvant chemotherapy is allowed if it has been more than 6 months since the treatment was finished and there have been no signs of disease progression, neither during treatment nor during the 6 months following its completion.
- •Adequate medullar reserve:
- •Absolute neutrophil count ≥ 1.5 x 109/L
- •Platelet count ≥ 100 x 109/L
- •Haemoglobin ≥ 9 g/dL
- •Adequate renal function: Creatinine clearance > 30 mL/min, calculated using the Cockroff-Gault formula, or a serum creatinine < 2 mg/dL or 177 umol/L
- •An adequate liver function: ASAT (SGOT) and ALAT (SGPT) ≤ 2.5 x ULN (≤ 5 x ULN if there are liver metastases). Total bilirubin < 1.5 x ULN. Alkaline phosphatase ≤ 2.5 x ULN ( ≤ 5 x ULN in the case of liver metastases or ≤ 10 x ULN in the case of bone metastases)
排除标准
- •To have received prior systemic treatment for the metastatic disease
- •Diagnosis or suspicion of brain or leptomeningeal metastases
- •Major surgery or radiotherapy (except for antalgic surgery that does not include measurable target lesions) during the 4 weeks prior to inclusion in the study.
- •Previous administration of monoclonal antibodies, agents inhibiting EGFR signal transduction or EGFR-targeted treatment.
- •Participation in another clinical trial with drugs within the previous 30 days.
- •Neoplasm in the 2 years prior to entering the study, except for non-melanoma skin carcinoma or in situ cervix carcinoma.
- •Evidence of previous acute hypersensitivity reaction of any degree to any of the treatment's components.
- •Clinically relevant peripheral neuropathy.
- •Signs and symptoms, at the moment of entering the study, of acute or subacute bowel obstruction.
- •A history of an acute episode of ischemic heart disease (angina or acute myocardial infarction) within the previous 12 months or an elevated risk of heart failure decompensation or uncontrolled arrhythmia.
- •Serious active infection, including active tuberculosis and HIV diagnosis.
- •Chronic immunological or hormonal treatment, except for hormone replacement treatment at physiological doses.
- •Known drug or alcohol abuse.
- •Legal incapacity or limited legal capacity.
- •Pregnancy or breastfeeding. Premenopausal women must have a negative pregnancy test in urine or blood before entering the trial. Patients and their partners must take contraceptive measures (hormonal, barrier, or abstinence) if the possibility of conception exists, during the study and for 3 months after the end of the treatment thereof.
- •Any geographical or social circumstance or any medical or psychological alteration that, in the investigator's opinion, will not allow the patient to conclude the study.
研究组 & 干预措施
Control
Active Comparator
mFOLFOX-6 + cetuximab until disease progression or early withdrawal.
干预措施: mFOLFOX-6 + cetuximab until disease progression or early withdrawal. (Drug)
Experimental
Experimental
8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.
干预措施: 8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal. (Drug)
结局指标
主要结局
progression-free survival
时间窗: 2010-2014
次要结局
- overall survival(2010-2014)
- disease's resectability (R0)(2010-2014)
- rate of objective responses(2010-2014)
- evaluate hypomagnesaemia as a predictive factor in the treatment's efficacy(2010-2014)
- Adverse events(2010-2014)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRCColorectal CancerNCT02394795Takeda823
已完成
2 期
Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver MetastasesLiver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal CancerNCT01836653EPS Corporation122
已完成
2 期
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line RegimenColorectal NeoplasmsNCT00615056Pfizer171
进行中（未招募）
2 期
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal AdenocarcinomaAdenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionAdenocarcinoma of the Gastric CardiaStage IIIA Esophageal CancerStage IIIB Esophageal CancerStage IIIC Esophageal CancerNCT02037048Case Comprehensive Cancer Center63
已完成
2 期
Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal CancerColon CancerNCT00193219SCRI Development Innovations, LLC36